Global Chemotherapy Market
Global Chemotherapy Market

Chemotherapy Comprehensive Study by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia, Ovarian Cancer, Others), Route of Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular, Intravesicular, Topical, Intraperitoneal, Intraventricular/Intrathecal), Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, Antitumor Antibiotic) Players and Region - Global Market Outlook to 2024

Chemotherapy Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 245 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

The chemotherapy is an aggressive form of chemical drug therapy meant to destroy rapidly growing cells in the body. It is generally used to treat the caner in which cancerous cell multiply faster than other cells. It is used in the combination with other therapies including surgery, radiation or hormone therapy. It has three main goals for chemotherapy includes cure, control and palliation of the cancer. The drugs used in the chemotherapy prevent cell division, targets the food sources of cancer cells such as the enzymes and hormones and triggers apoptosis.

The market study is being classified, by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia, Ovarian Cancer and Others) and major geographies with country level break-up.

Novartis AG (Switzerland), Pfizer Inc. (United States), Johnson & Johnson Services Inc. (United States), Bristol-Myers Squibb Company (United States), GlaxoSmithKline PLC (United Kingdom), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co. Inc. (United States), Sanofi S.A. (France) and Celgene Corporation (United States) are some of the key players profiled in the study.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Chemotherapy market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Chemotherapy market by Type, Application and Region.

On the basis of geography, the market of Chemotherapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Cancer Disease
  • Government Initiatives for Cancer Research
  • Growing Awareness about the Caners Leads into Early Detection of the Disease


Restraints
  • Side Effects of the Chemotherapy on Human Body

Opportunities
  • Increasing Number of Hospitals and Clinics Providing Chemotherapy
  • Growing Health Insurance Industry

Challenges
  • Lack of Healthcare Facilities for Chemotherapy in the Many Hospitals of Developing Countries





Key Target Audience
Chemotherapy Drug Manufacturers, Research Professionals, Emerging Companies, Government Body & Associations and End-user

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Lymphoma
  • Leukemia
  • Ovarian Cancer
  • Others
By Route of Administration
  • Intravenous
  • Oral
  • Subcutaneous
  • Intra-Muscular
  • Intravesicular
  • Topical
  • Intraperitoneal
  • Intraventricular/Intrathecal

By Drug Class
  • Alkylating Agents
  • Mitotic Inhibitors
  • Antimetabolites
  • Topoisomerase Inhibitors
  • Antitumor Antibiotic

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cancer Disease
      • 3.2.2. Government Initiatives for Cancer Research
      • 3.2.3. Growing Awareness about the Caners Leads into Early Detection of the Disease
    • 3.3. Market Challenges
      • 3.3.1. Lack of Healthcare Facilities for Chemotherapy in the Many Hospitals of Developing Countries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chemotherapy, by Application, Route of Administration, Drug Class and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Chemotherapy (Value)
      • 5.2.1. Global Chemotherapy by: Application (Value)
        • 5.2.1.1. Lung Cancer
        • 5.2.1.2. Breast Cancer
        • 5.2.1.3. Colorectal Cancer
        • 5.2.1.4. Prostate Cancer
        • 5.2.1.5. Stomach Cancer
        • 5.2.1.6. Lymphoma
        • 5.2.1.7. Leukemia
        • 5.2.1.8. Ovarian Cancer
        • 5.2.1.9. Others
      • 5.2.2. Global Chemotherapy by: Route of Administration (Value)
        • 5.2.2.1. Intravenous
        • 5.2.2.2. Oral
        • 5.2.2.3. Subcutaneous
        • 5.2.2.4. Intra-Muscular
        • 5.2.2.5. Intravesicular
        • 5.2.2.6. Topical
        • 5.2.2.7. Intraperitoneal
        • 5.2.2.8. Intraventricular/Intrathecal
      • 5.2.3. Global Chemotherapy by: Drug Class (Value)
        • 5.2.3.1. Alkylating Agents
        • 5.2.3.2. Mitotic Inhibitors
        • 5.2.3.3. Antimetabolites
        • 5.2.3.4. Topoisomerase Inhibitors
        • 5.2.3.5. Antitumor Antibiotic
      • 5.2.4. Global Chemotherapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Chemotherapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson Services Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Myers Squibb Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co. Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi S.A. (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Celgene Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Chemotherapy Sale, by Application, Route of Administration, Drug Class and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Chemotherapy (Value)
      • 7.2.1. Global Chemotherapy by: Application (Value)
        • 7.2.1.1. Lung Cancer
        • 7.2.1.2. Breast Cancer
        • 7.2.1.3. Colorectal Cancer
        • 7.2.1.4. Prostate Cancer
        • 7.2.1.5. Stomach Cancer
        • 7.2.1.6. Lymphoma
        • 7.2.1.7. Leukemia
        • 7.2.1.8. Ovarian Cancer
        • 7.2.1.9. Others
      • 7.2.2. Global Chemotherapy by: Route of Administration (Value)
        • 7.2.2.1. Intravenous
        • 7.2.2.2. Oral
        • 7.2.2.3. Subcutaneous
        • 7.2.2.4. Intra-Muscular
        • 7.2.2.5. Intravesicular
        • 7.2.2.6. Topical
        • 7.2.2.7. Intraperitoneal
        • 7.2.2.8. Intraventricular/Intrathecal
      • 7.2.3. Global Chemotherapy by: Drug Class (Value)
        • 7.2.3.1. Alkylating Agents
        • 7.2.3.2. Mitotic Inhibitors
        • 7.2.3.3. Antimetabolites
        • 7.2.3.4. Topoisomerase Inhibitors
        • 7.2.3.5. Antitumor Antibiotic
      • 7.2.4. Global Chemotherapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chemotherapy: by Application(USD Million)
  • Table 2. Chemotherapy Lung Cancer , by Region USD Million (2013-2018)
  • Table 3. Chemotherapy Breast Cancer , by Region USD Million (2013-2018)
  • Table 4. Chemotherapy Colorectal Cancer , by Region USD Million (2013-2018)
  • Table 5. Chemotherapy Prostate Cancer , by Region USD Million (2013-2018)
  • Table 6. Chemotherapy Stomach Cancer , by Region USD Million (2013-2018)
  • Table 7. Chemotherapy Lymphoma , by Region USD Million (2013-2018)
  • Table 8. Chemotherapy Leukemia , by Region USD Million (2013-2018)
  • Table 9. Chemotherapy Ovarian Cancer , by Region USD Million (2013-2018)
  • Table 10. Chemotherapy Others , by Region USD Million (2013-2018)
  • Table 11. Chemotherapy: by Route of Administration(USD Million)
  • Table 12. Chemotherapy Intravenous , by Region USD Million (2013-2018)
  • Table 13. Chemotherapy Oral , by Region USD Million (2013-2018)
  • Table 14. Chemotherapy Subcutaneous , by Region USD Million (2013-2018)
  • Table 15. Chemotherapy Intra-Muscular , by Region USD Million (2013-2018)
  • Table 16. Chemotherapy Intravesicular , by Region USD Million (2013-2018)
  • Table 17. Chemotherapy Topical , by Region USD Million (2013-2018)
  • Table 18. Chemotherapy Intraperitoneal , by Region USD Million (2013-2018)
  • Table 19. Chemotherapy Intraventricular/Intrathecal , by Region USD Million (2013-2018)
  • Table 20. Chemotherapy: by Drug Class(USD Million)
  • Table 21. Chemotherapy Alkylating Agents , by Region USD Million (2013-2018)
  • Table 22. Chemotherapy Mitotic Inhibitors , by Region USD Million (2013-2018)
  • Table 23. Chemotherapy Antimetabolites , by Region USD Million (2013-2018)
  • Table 24. Chemotherapy Topoisomerase Inhibitors , by Region USD Million (2013-2018)
  • Table 25. Chemotherapy Antitumor Antibiotic , by Region USD Million (2013-2018)
  • Table 26. South America Chemotherapy, by Country USD Million (2013-2018)
  • Table 27. South America Chemotherapy, by Application USD Million (2013-2018)
  • Table 28. South America Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 29. South America Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 30. Brazil Chemotherapy, by Application USD Million (2013-2018)
  • Table 31. Brazil Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 32. Brazil Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 33. Argentina Chemotherapy, by Application USD Million (2013-2018)
  • Table 34. Argentina Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 35. Argentina Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 36. Rest of South America Chemotherapy, by Application USD Million (2013-2018)
  • Table 37. Rest of South America Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 38. Rest of South America Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 39. Asia Pacific Chemotherapy, by Country USD Million (2013-2018)
  • Table 40. Asia Pacific Chemotherapy, by Application USD Million (2013-2018)
  • Table 41. Asia Pacific Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 42. Asia Pacific Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 43. China Chemotherapy, by Application USD Million (2013-2018)
  • Table 44. China Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 45. China Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 46. Japan Chemotherapy, by Application USD Million (2013-2018)
  • Table 47. Japan Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 48. Japan Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 49. India Chemotherapy, by Application USD Million (2013-2018)
  • Table 50. India Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 51. India Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 52. South Korea Chemotherapy, by Application USD Million (2013-2018)
  • Table 53. South Korea Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 54. South Korea Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 55. Taiwan Chemotherapy, by Application USD Million (2013-2018)
  • Table 56. Taiwan Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 57. Taiwan Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 58. Australia Chemotherapy, by Application USD Million (2013-2018)
  • Table 59. Australia Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 60. Australia Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 61. Rest of Asia-Pacific Chemotherapy, by Application USD Million (2013-2018)
  • Table 62. Rest of Asia-Pacific Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 63. Rest of Asia-Pacific Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 64. Europe Chemotherapy, by Country USD Million (2013-2018)
  • Table 65. Europe Chemotherapy, by Application USD Million (2013-2018)
  • Table 66. Europe Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 67. Europe Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 68. Germany Chemotherapy, by Application USD Million (2013-2018)
  • Table 69. Germany Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 70. Germany Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 71. France Chemotherapy, by Application USD Million (2013-2018)
  • Table 72. France Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 73. France Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 74. Italy Chemotherapy, by Application USD Million (2013-2018)
  • Table 75. Italy Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 76. Italy Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 77. United Kingdom Chemotherapy, by Application USD Million (2013-2018)
  • Table 78. United Kingdom Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 79. United Kingdom Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 80. Netherlands Chemotherapy, by Application USD Million (2013-2018)
  • Table 81. Netherlands Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 82. Netherlands Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 83. Rest of Europe Chemotherapy, by Application USD Million (2013-2018)
  • Table 84. Rest of Europe Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 85. Rest of Europe Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 86. MEA Chemotherapy, by Country USD Million (2013-2018)
  • Table 87. MEA Chemotherapy, by Application USD Million (2013-2018)
  • Table 88. MEA Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 89. MEA Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 90. Middle East Chemotherapy, by Application USD Million (2013-2018)
  • Table 91. Middle East Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 92. Middle East Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 93. Africa Chemotherapy, by Application USD Million (2013-2018)
  • Table 94. Africa Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 95. Africa Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 96. North America Chemotherapy, by Country USD Million (2013-2018)
  • Table 97. North America Chemotherapy, by Application USD Million (2013-2018)
  • Table 98. North America Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 99. North America Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 100. United States Chemotherapy, by Application USD Million (2013-2018)
  • Table 101. United States Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 102. United States Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 103. Canada Chemotherapy, by Application USD Million (2013-2018)
  • Table 104. Canada Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 105. Canada Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 106. Mexico Chemotherapy, by Application USD Million (2013-2018)
  • Table 107. Mexico Chemotherapy, by Route of Administration USD Million (2013-2018)
  • Table 108. Mexico Chemotherapy, by Drug Class USD Million (2013-2018)
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Chemotherapy: by Application(USD Million)
  • Table 120. Chemotherapy Lung Cancer , by Region USD Million (2019-2024)
  • Table 121. Chemotherapy Breast Cancer , by Region USD Million (2019-2024)
  • Table 122. Chemotherapy Colorectal Cancer , by Region USD Million (2019-2024)
  • Table 123. Chemotherapy Prostate Cancer , by Region USD Million (2019-2024)
  • Table 124. Chemotherapy Stomach Cancer , by Region USD Million (2019-2024)
  • Table 125. Chemotherapy Lymphoma , by Region USD Million (2019-2024)
  • Table 126. Chemotherapy Leukemia , by Region USD Million (2019-2024)
  • Table 127. Chemotherapy Ovarian Cancer , by Region USD Million (2019-2024)
  • Table 128. Chemotherapy Others , by Region USD Million (2019-2024)
  • Table 129. Chemotherapy: by Route of Administration(USD Million)
  • Table 130. Chemotherapy Intravenous , by Region USD Million (2019-2024)
  • Table 131. Chemotherapy Oral , by Region USD Million (2019-2024)
  • Table 132. Chemotherapy Subcutaneous , by Region USD Million (2019-2024)
  • Table 133. Chemotherapy Intra-Muscular , by Region USD Million (2019-2024)
  • Table 134. Chemotherapy Intravesicular , by Region USD Million (2019-2024)
  • Table 135. Chemotherapy Topical , by Region USD Million (2019-2024)
  • Table 136. Chemotherapy Intraperitoneal , by Region USD Million (2019-2024)
  • Table 137. Chemotherapy Intraventricular/Intrathecal , by Region USD Million (2019-2024)
  • Table 138. Chemotherapy: by Drug Class(USD Million)
  • Table 139. Chemotherapy Alkylating Agents , by Region USD Million (2019-2024)
  • Table 140. Chemotherapy Mitotic Inhibitors , by Region USD Million (2019-2024)
  • Table 141. Chemotherapy Antimetabolites , by Region USD Million (2019-2024)
  • Table 142. Chemotherapy Topoisomerase Inhibitors , by Region USD Million (2019-2024)
  • Table 143. Chemotherapy Antitumor Antibiotic , by Region USD Million (2019-2024)
  • Table 144. South America Chemotherapy, by Country USD Million (2019-2024)
  • Table 145. South America Chemotherapy, by Application USD Million (2019-2024)
  • Table 146. South America Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 147. South America Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 148. Brazil Chemotherapy, by Application USD Million (2019-2024)
  • Table 149. Brazil Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 150. Brazil Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 151. Argentina Chemotherapy, by Application USD Million (2019-2024)
  • Table 152. Argentina Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 153. Argentina Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 154. Rest of South America Chemotherapy, by Application USD Million (2019-2024)
  • Table 155. Rest of South America Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 156. Rest of South America Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 157. Asia Pacific Chemotherapy, by Country USD Million (2019-2024)
  • Table 158. Asia Pacific Chemotherapy, by Application USD Million (2019-2024)
  • Table 159. Asia Pacific Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 160. Asia Pacific Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 161. China Chemotherapy, by Application USD Million (2019-2024)
  • Table 162. China Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 163. China Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 164. Japan Chemotherapy, by Application USD Million (2019-2024)
  • Table 165. Japan Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 166. Japan Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 167. India Chemotherapy, by Application USD Million (2019-2024)
  • Table 168. India Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 169. India Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 170. South Korea Chemotherapy, by Application USD Million (2019-2024)
  • Table 171. South Korea Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 172. South Korea Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 173. Taiwan Chemotherapy, by Application USD Million (2019-2024)
  • Table 174. Taiwan Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 175. Taiwan Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 176. Australia Chemotherapy, by Application USD Million (2019-2024)
  • Table 177. Australia Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 178. Australia Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 179. Rest of Asia-Pacific Chemotherapy, by Application USD Million (2019-2024)
  • Table 180. Rest of Asia-Pacific Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 181. Rest of Asia-Pacific Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 182. Europe Chemotherapy, by Country USD Million (2019-2024)
  • Table 183. Europe Chemotherapy, by Application USD Million (2019-2024)
  • Table 184. Europe Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 185. Europe Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 186. Germany Chemotherapy, by Application USD Million (2019-2024)
  • Table 187. Germany Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 188. Germany Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 189. France Chemotherapy, by Application USD Million (2019-2024)
  • Table 190. France Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 191. France Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 192. Italy Chemotherapy, by Application USD Million (2019-2024)
  • Table 193. Italy Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 194. Italy Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 195. United Kingdom Chemotherapy, by Application USD Million (2019-2024)
  • Table 196. United Kingdom Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 197. United Kingdom Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 198. Netherlands Chemotherapy, by Application USD Million (2019-2024)
  • Table 199. Netherlands Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 200. Netherlands Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 201. Rest of Europe Chemotherapy, by Application USD Million (2019-2024)
  • Table 202. Rest of Europe Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 203. Rest of Europe Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 204. MEA Chemotherapy, by Country USD Million (2019-2024)
  • Table 205. MEA Chemotherapy, by Application USD Million (2019-2024)
  • Table 206. MEA Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 207. MEA Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 208. Middle East Chemotherapy, by Application USD Million (2019-2024)
  • Table 209. Middle East Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 210. Middle East Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 211. Africa Chemotherapy, by Application USD Million (2019-2024)
  • Table 212. Africa Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 213. Africa Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 214. North America Chemotherapy, by Country USD Million (2019-2024)
  • Table 215. North America Chemotherapy, by Application USD Million (2019-2024)
  • Table 216. North America Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 217. North America Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 218. United States Chemotherapy, by Application USD Million (2019-2024)
  • Table 219. United States Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 220. United States Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 221. Canada Chemotherapy, by Application USD Million (2019-2024)
  • Table 222. Canada Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 223. Canada Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 224. Mexico Chemotherapy, by Application USD Million (2019-2024)
  • Table 225. Mexico Chemotherapy, by Route of Administration USD Million (2019-2024)
  • Table 226. Mexico Chemotherapy, by Drug Class USD Million (2019-2024)
  • Table 227. Research Programs/Design for This Report
  • Table 228. Key Data Information from Secondary Sources
  • Table 229. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chemotherapy: by Application USD Million (2013-2018)
  • Figure 5. Global Chemotherapy: by Route of Administration USD Million (2013-2018)
  • Figure 6. Global Chemotherapy: by Drug Class USD Million (2013-2018)
  • Figure 7. South America Chemotherapy Share (%), by Country
  • Figure 8. Asia Pacific Chemotherapy Share (%), by Country
  • Figure 9. Europe Chemotherapy Share (%), by Country
  • Figure 10. MEA Chemotherapy Share (%), by Country
  • Figure 11. North America Chemotherapy Share (%), by Country
  • Figure 12. Global Chemotherapy share by Players 2018 (%)
  • Figure 13. Global Chemotherapy share by Players (Top 3) 2018(%)
  • Figure 14. Global Chemotherapy share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 20. Johnson & Johnson Services Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson Services Inc. (United States) Revenue: by Geography 2018
  • Figure 22. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2018
  • Figure 24. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2018
  • Figure 26. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 28. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2018
  • Figure 30. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck & Co. Inc. (United States) Revenue: by Geography 2018
  • Figure 32. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi S.A. (France) Revenue: by Geography 2018
  • Figure 34. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 35. Celgene Corporation (United States) Revenue: by Geography 2018
  • Figure 36. Global Chemotherapy: by Application USD Million (2019-2024)
  • Figure 37. Global Chemotherapy: by Route of Administration USD Million (2019-2024)
  • Figure 38. Global Chemotherapy: by Drug Class USD Million (2019-2024)
  • Figure 39. South America Chemotherapy Share (%), by Country
  • Figure 40. Asia Pacific Chemotherapy Share (%), by Country
  • Figure 41. Europe Chemotherapy Share (%), by Country
  • Figure 42. MEA Chemotherapy Share (%), by Country
  • Figure 43. North America Chemotherapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Johnson & Johnson Services Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Eli Lilly and Company (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Merck & Co. Inc. (United States)
  • Sanofi S.A. (France)
  • Celgene Corporation (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation